Achieve Life Sciences (NASDAQ:ACHV) Receives “Buy” Rating from LADENBURG THALM/SH SH

LADENBURG THALM/SH SH reissued their buy rating on shares of Achieve Life Sciences (NASDAQ:ACHV) in a report issued on Friday morning, AnalystRatings.com reports. LADENBURG THALM/SH SH currently has a $20.00 target price on the biopharmaceutical company’s stock.

ACHV has been the subject of several other research reports. ValuEngine upgraded Achieve Life Sciences from a sell rating to a hold rating in a report on Thursday, August 1st. Maxim Group restated a buy rating and issued a $6.00 price objective on shares of Achieve Life Sciences in a report on Wednesday, July 24th.

Shares of ACHV traded down $0.10 during midday trading on Friday, hitting $1.75. The stock had a trading volume of 137,911 shares, compared to its average volume of 92,322. The firm has a 50 day moving average of $1.91. Achieve Life Sciences has a twelve month low of $1.04 and a twelve month high of $5.25. The firm has a market capitalization of $14.18 million, a price-to-earnings ratio of -0.48 and a beta of 2.07. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 0.03.

Achieve Life Sciences (NASDAQ:ACHV) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.17). On average, sell-side analysts predict that Achieve Life Sciences will post -1.7 earnings per share for the current fiscal year.

In other Achieve Life Sciences news, major shareholder Armistice Capital Master Fund purchased 12,813 shares of Achieve Life Sciences stock in a transaction that occurred on Tuesday, June 11th. The stock was acquired at an average price of $3.80 per share, for a total transaction of $48,689.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Richard Alistair Stewart purchased 17,500 shares of Achieve Life Sciences stock in a transaction that occurred on Thursday, May 23rd. The shares were acquired at an average price of $3.61 per share, with a total value of $63,175.00. The disclosure for this purchase can be found here. 6.80% of the stock is owned by company insiders.

An institutional investor recently bought a new position in Achieve Life Sciences stock. Searle & CO. purchased a new position in shares of Achieve Life Sciences Inc (NASDAQ:ACHV) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 73,500 shares of the biopharmaceutical company’s stock, valued at approximately $237,000. Searle & CO. owned 1.09% of Achieve Life Sciences as of its most recent filing with the Securities & Exchange Commission. 14.47% of the stock is owned by hedge funds and other institutional investors.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.

See Also: Compound Interest

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.